BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 32863940)

  • 1. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
    Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
    [No Abstract]   [Full Text] [Related]  

  • 2. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
    Engert F; Kovac M; Baumhoer D; Nathrath M; Fulda S
    Oncotarget; 2017 Jul; 8(30):48794-48806. PubMed ID: 27447864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
    J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
    Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human mass balance study and metabolite profiling of
    van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
    Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
    AlHilli MM; Becker MA; Weroha SJ; Flatten KS; Hurley RM; Harrell MI; Oberg AL; Maurer MJ; Hawthorne KM; Hou X; Harrington SC; McKinstry S; Meng XW; Wilcoxen KM; Kalli KR; Swisher EM; Kaufmann SH; Haluska P
    Gynecol Oncol; 2016 Nov; 143(2):379-388. PubMed ID: 27614696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
    Gou R; Dong H; Lin B
    Life Sci; 2020 Nov; 261():118434. PubMed ID: 32941897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response.
    Moore JA; Chen KT; Madison R; Newberg JY; Fleischmann Z; Wang S; Sharaf R; Murugesan K; Fendler BJ; Hughes J; Schrock AB; Hegde PS; Oxnard GR; Fabrizio D; Frampton GM; Antonarakis ES; Sokol ES; Jin DX
    JCO Precis Oncol; 2023 Sep; 7():e2300093. PubMed ID: 37769224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
    Meijer TG; Nguyen L; Van Hoeck A; Sieuwerts AM; Verkaik NS; Ladan MM; Ruigrok-Ritstier K; van Deurzen CHM; van de Werken HJG; Lips EH; Linn SC; Memari Y; Davies H; Nik-Zainal S; Kanaar R; Martens JWM; Cuppen E; Jager A; van Gent DC
    Oncogene; 2022 Jun; 41(26):3498-3506. PubMed ID: 35662281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MOF@COF Nanocapsules Enhance Soft Tissue Sarcoma Treatment: Synergistic Effects of Photodynamic Therapy and PARP Inhibition on Tumor Growth Suppression and Immune Response Activation.
    Tai Y; Chen Z; Luo T; Luo B; Deng C; Lu Z; Wen S; Wang J
    Adv Healthc Mater; 2024 Apr; 13(11):e2303911. PubMed ID: 38215731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality.
    Murai J; Pommier Y
    Cancer Res; 2023 Apr; 83(8):1173-1174. PubMed ID: 37057596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma.
    Planas-Paz L; Pliego-Mendieta A; Hagedorn C; Aguilera-Garcia D; Haberecker M; Arnold F; Herzog M; Bankel L; Guggenberger R; Steiner S; Chen Y; Kahraman A; Zoche M; Rubin MA; Moch H; Britschgi C; Pauli C
    EMBO Mol Med; 2023 Apr; 15(4):e16863. PubMed ID: 36779660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors.
    Mangoni M; Sottili M; Salvatore G; Meattini I; Desideri I; Greto D; Loi M; Becherini C; Garlatti P; Delli Paoli C; Dominici L; Gerini C; Scoccianti S; Bonomo P; Silvano A; Beltrami G; Campanacci D; Livi L
    Radiat Res; 2018 Nov; 190(5):464-472. PubMed ID: 30067444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
    Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
    J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous recombination repair deficiency as a therapeutic target in sarcoma.
    Oza J; Doshi SD; Hao L; Musi E; Schwartz GK; Ingham M
    Semin Oncol; 2020 Dec; 47(6):380-389. PubMed ID: 33183763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
    Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity.
    Smeby J; Kryeziu K; Berg KCG; Eilertsen IA; Eide PW; Johannessen B; Guren MG; Nesbakken A; Bruun J; Lothe RA; Sveen A
    EBioMedicine; 2020 Sep; 59():102923. PubMed ID: 32799124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
    Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD
    BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.